Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL5863178 | 0.95 | KDM4E (0.43) | HTTKCNA5MAPK1SLC6A5NPC1 | |
| Oxalic Acid SCHEMBL5863050 | 0.92 | KCNA5 (0.43) | HTTKCNA5MAPK1NPC1RAB9A | |
| SCHEMBL5863052 | 0.87 | KDM4E (0.45) | HTTMAPK1SLC6A5NPC1RAB9A | |
| SCHEMBL5863100 | 0.87 | FYN (0.46) | NPC1RAB9AKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL5863055 | 0.85 | KDM4E (0.42) | HTTMAPK1NPC1RAB9AKDM4E | |
| SCHEMBL5863455 | 0.84 | MCHR1 (0.42) | HTTKDM4ESMN1; SMN2MCHR1ALDH1A1 | |
| SCHEMBL5863072 | 0.84 | NPC1 (0.45) | NPC1RAB9AKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL5637477 | 0.83 | HTT (0.40) | HTTMAPK1NPC1RAB9AALOX15 | |
| Oxalic Acid SCHEMBL5863262 | 0.83 | FYN (0.46) | NPC1RAB9AKDM4EKMT2ASMN1; SMN2 | |
| Oxalic Acid SCHEMBL5863081 | 0.82 | KDM4E (0.44) | SLC6A5NPC1RAB9AKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132456-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060052449-A1 | Novel mch receptor antagonists | ELI LILLY AND COMPANY | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052449-A1 | Novel mch receptor antagonists | MCHR1, MCHR2, MC1R | HTT 308/4885KCNA5 1296/4885MAPK1 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.